Abbott Will Present Two-Year Follow-Up Data At Xience FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Abbott expects to present two-year data for several hundred Xience V everolimus-eluting stent patients at a Nov. 29 meeting with an FDA advisory panel, the firm announced Oct. 17
You may also be interested in...
Panel Advises 5,000-Patient Postmarket Study For Medtronic’s DES
Medtronic should conduct a large postmarket study to monitor late stent thrombosis and help define the appropriate antiplatelet drug regimen for drug-eluting stent patients, FDA's Circulatory System Devices Panel recommended at its Oct. 10 meeting in Gaithersburg, Md
GE And Abbott Walk Away From $8 Billion Diagnostics Deal
Abbott says it will continue to manage its core laboratory and point-of-care diagnostics business for the long-term following the collapse of an $8.13 billion deal to sell the unit to General Electric
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.